Polynucleotides and PDRN: The Complete Practitioner's Guide

Polynucleotides — sold under a variety of brand names and delivered through a growing range of injection products — have become one of the most talked-about categories in UK aesthetic medicine. They are also one of the most misunderstood. Practitioners encounter them under different terminology (PDRN, PN, polynucleotide, polydeoxyribonucleotide), from multiple manufacturers, with variable claimed mechanisms, and with an evidence base that ranges from well-established to preliminary depending on the specific application and product.

At the same time, the clinical results that well-selected, well-executed polynucleotide treatments produce are among the most consistently impressive in non-surgical aesthetics — particularly for patients whose skin quality concerns are not adequately addressed by HA skin boosters, toxin, or filler alone. For skin quality improvement driven by genuine collagen deficit and cellular ageing, polynucleotides address the problem at a biological level that no other injectable currently matches.

This guide provides a complete clinical foundation: what polynucleotides and PDRN are, how they work, what the evidence shows, which patients benefit most, how to administer them, and how Korean PDRN/PN products — available through Celmade's PDRN and PN range — compare to European alternatives. It is the pillar post for Celmade's PDRN/Polynucleotide content cluster, with in-depth cluster posts linked throughout.

What Are Polynucleotides and PDRN? Defining the Category

The terminology in this category requires careful definition — practitioners and patients often use terms interchangeably that have distinct technical meanings:

DNA and Polynucleotides

Deoxyribonucleic acid (DNA) is a polymer composed of nucleotide units, each consisting of a deoxyribose sugar, a phosphate group, and one of four nitrogenous bases (adenine, thymine, guanine, cytosine). Polynucleotides (PN) are simply chains of nucleotides — in the context of aesthetic injectables, these are DNA fragments extracted from salmon or trout sperm (polydeoxyribonucleotides — hence PDRN), purified, and processed for injection.

PDRN — Polydeoxyribonucleotide

PDRN is the specific term for the fraction of polynucleotides most relevant to aesthetic and regenerative medicine. It refers to depolymerised DNA fragments in a specific molecular weight range (80–1,000 kDa) that have been shown to stimulate tissue regeneration through the adenosine A2A receptor pathway. PDRN is the active category used in most aesthetic injectable products marketed as polynucleotides.

Why Salmon or Trout?

Salmon and trout sperm DNA is used because its nucleotide sequence is highly homologous (95%+) to human DNA. This means the fragments, when injected into human tissue, are not identified as foreign antigens by the immune system — making them well-tolerated with a very low immunogenicity risk. The high homology also means the nucleotide building blocks released during PDRN metabolism are directly available for human cellular DNA synthesis and repair.

Mechanism of Action: How PDRN Regenerates Tissue

PDRN's clinical effects are driven by two distinct and complementary mechanisms that operate simultaneously after injection:

Mechanism 1: Adenosine A2A Receptor Activation

The primary and most well-characterised mechanism of PDRN is activation of the adenosine A2A receptor (A2AR) — a G-protein coupled receptor present on fibroblasts, endothelial cells, macrophages, and other tissue-resident cells. PDRN fragments activate A2AR through a mechanism analogous to adenosine itself, triggering a downstream signalling cascade that produces:

•        Fibroblast proliferation: Direct stimulation of fibroblast cell division increases the population of collagen-producing cells in the treated tissue.

•        VEGF (Vascular Endothelial Growth Factor) upregulation: A2AR activation increases VEGF expression, stimulating angiogenesis — new blood vessel formation. Improved vascular supply increases nutrient and oxygen delivery to the treated tissue, supporting fibroblast function and overall tissue health.

•        Collagen and elastin synthesis: Activated fibroblasts produce more Type I and Type III collagen and more elastin, directly rebuilding the dermal structural protein matrix.

•        Anti-inflammatory and anti-apoptotic signalling: A2AR activation suppresses pro-inflammatory cytokines and protects cells from programmed cell death, creating a tissue environment that favours regeneration over inflammation.

The landmark work establishing PDRN's A2AR-mediated mechanism includes the foundational studies by Thellung et al. (1999) in Drug Development Research and the subsequent wound healing research by Sini et al. (2005) in the Journal of Investigative Dermatology demonstrating PDRN's ability to accelerate dermal wound healing through A2AR activation and VEGF upregulation.

Mechanism 2: Salvage Pathway Nucleotide Supply

The second mechanism is indirect and operates over a longer timeframe. As PDRN fragments are metabolised by endogenous nucleases in the tissue, they are broken down into their component nucleotides — the building blocks of DNA and RNA. These nucleotides enter the salvage pathway — the cell's recycling mechanism for nucleotides — and become directly available for:

•        DNA replication in dividing cells (including newly proliferating fibroblasts)

•        RNA synthesis for cellular protein production

•        Direct cellular energy production (ATP synthesis)

This salvage pathway supply means that PDRN does not just trigger regeneration — it also provides the biological raw materials that regenerating cells require to complete the repair and remodelling process. This dual mechanism (trigger + supply) is what distinguishes PDRN from most other regenerative injectable agents, which typically act as triggers without providing material support for the downstream repair process.

PDRN vs HA Skin Boosters: Mechanism Comparison

Understanding where PDRN sits relative to HA skin boosters — and how they can be combined — requires a clear side-by-side mechanism comparison:

For the full side-by-side clinical discussion of these two treatment categories, see our Skin Boosters: Complete Practitioner's Guide and our post on Combining Skin Boosters with Other Treatments.

The Clinical Evidence Base for PDRN in Aesthetic Medicine

PDRN has the most established evidence base of any injectable in this product category. The evidence spans from basic science (in vitro cell studies) through animal models to human clinical trials, with an increasingly robust body of aesthetic-specific RCT data:

Wound Healing and Dermal Regeneration

The original therapeutic application of PDRN was wound healing — and this is where the strongest Level 1 evidence exists. Multiple RCTs have demonstrated PDRN's superiority over placebo and comparable treatments in accelerating healing of diabetic foot ulcers, surgical wounds, and burns. The mechanisms confirmed in this evidence — A2AR-mediated VEGF upregulation, fibroblast proliferation, collagen synthesis — are the same mechanisms relevant to aesthetic skin quality improvement.

Aesthetic Skin Quality Improvement

The aesthetic evidence base is growing rapidly. Key clinical studies include:

•        Gazzola et al. (2012) in the Journal of Drugs in Dermatology — demonstrating significant improvement in skin hydration, elasticity, and wrinkle depth after a series of PDRN intradermal injections in a controlled patient population.

•        Veronesi et al. (2017) in Journal of Biological Regulators and Homeostatic Agents — showing significant skin quality improvement with PDRN treatment compared to HA alone, particularly in elasticity and fine line depth measurements.

•        Korean clinical data — published in Korean dermatological and plastic surgery journals — provides extensive real-world outcome data from the large-scale domestic Korean market where PDRN/PN products have been used for over 15 years. This body of evidence, while not always accessible in English, underpins the clinical confidence of Korean manufacturers and the global export of Korean PDRN products.

Hair Rejuvenation

PDRN's angiogenic and fibroblast-stimulating properties make it effective for scalp treatment in patients with androgenetic alopecia and diffuse hair thinning. The improved blood supply to hair follicles stimulated by VEGF upregulation, combined with the anti-apoptotic protection of follicle cells, has produced meaningful clinical outcomes in multiple studies. For practitioners looking to expand into hair rejuvenation, PDRN represents one of the most evidence-supported injectable options available.

For the dedicated hair rejuvenation guide, see our PDRN for Hair Rejuvenation: Protocol and Evidence.

Clinical Indications: Where PDRN Produces the Best Outcomes

Contraindications and Precautions

Absolute Contraindications

•        Active skin infection, inflammation, or open wound at the proposed injection site

•        Known hypersensitivity to salmon or fish-derived products (relevant to salmon-source PDRN)

•        Active autoimmune condition with skin involvement

•        Pregnancy — defer as precautionary measure

•        Active malignancy — adenosine A2A receptor activation promotes cell proliferation; avoid in active cancer

Relative Contraindications and Precautions

•        Anticoagulant medications: Increased bruising risk. Inform patients but do not discontinue anticoagulants without medical review.

•        History of keloid or hypertrophic scarring: Potent fibroblast stimulation may theoretically increase risk in predisposed patients. Assess scar history.

•        Immunosuppressive therapy: The regenerative cellular response may be attenuated in significantly immunosuppressed patients. Manage expectations accordingly.

•        Fish allergy: Although PDRN is processed DNA (not fish protein), severe fish allergy warrants caution. Verify with the patient and product documentation.

PDRN Injection Technique: Protocol and Administration

PDRN injection technique shares some principles with skin booster nappage but has specific differences determined by the product's different viscosity profile and clinical objectives:

Standard Intradermal Nappage Protocol

For skin quality improvement across the face, neck, or décolletage:

•        Needle gauge: 30G or 31G. PDRN products are typically lower viscosity than HA skin boosters and flow readily through fine needles.

•        Injection angle: 30–45 degrees for standard face nappage. 15–20 degrees for periorbital.

•        Volume per point: 0.02–0.05ml per point — slightly higher per point than standard HA nappage because PDRN does not create a visible papule in the same way HA does.

•        Point spacing: 1–1.5cm across the treatment zone in a regular grid pattern.

•        Depth confirmation: PDRN products may produce smaller or less visible papules than HA products at equivalent volumes. Use a consistent angle and insertion depth rather than relying solely on papule visibility for depth confirmation.

•        Total volume per session (full face): 2–4ml for a full face treatment, depending on the product concentration and clinical presentation.

Periorbital Protocol

PDRN is the preferred primary product for periorbital biorevitalisation in most patients — its absence of hydrophilicity eliminates the oedema risk that makes standard HA skin boosters problematic in this zone. For the complete periorbital protocol, see our dedicated post: PDRN for Under-Eye Rejuvenation: Protocol and Product Selection.

Scalp Protocol for Hair Rejuvenation

For hair rejuvenation applications, the scalp protocol differs from facial nappage:

•        Needle gauge: 30G or 31G. Scalp skin is thicker than facial skin — standard needle length is appropriate.

•        Injection depth: Intradermal to subdermal — at the level of the hair follicle bulge zone (1–2mm below skin surface in the scalp).

•        Volume per point: 0.02–0.05ml per point.

•        Distribution: Treat the area of concern systematically — for diffuse thinning, full scalp coverage; for focal thinning, target the affected zone.

•        Session frequency: Monthly sessions for 4–6 sessions in the induction phase. Maintenance every 3–4 months.

Treatment Protocol — Standard Skin Quality Induction

Korean PDRN Products: The Global Clinical Standard

South Korea is the world's leading producer and exporter of pharmaceutical-grade PDRN products. The Korean PDRN market has been established for over 15 years, with extensive domestic clinical experience across tens of thousands of patients — a real-world evidence base that exceeds the published clinical trial data from any single manufacturer or country.

Korean PDRN manufacturers operate under MFDS (Ministry of Food and Drug Safety) pharmaceutical manufacturing oversight — equivalent to the EMA or FDA in its regulatory rigour. Products exported to the UK and EU must additionally hold CE marking as Class III medical devices, confirming assessment against European medical device regulation standards. Products available through Celmade's PDRN and PN range meet both MFDS and CE marking requirements.

What Distinguishes Korean PDRN Products

•        Purity standards: Korean pharmaceutical-grade PDRN undergoes extensive purification to remove proteins, lipids, and residual cellular material from the source salmon sperm DNA. The purification process is validated and documented as part of MFDS approval.

•        Molecular weight specification: The PDRN molecular weight range (typically 80–1,000 kDa for the clinically active fraction) is specified and controlled during manufacturing. This MW control is critical to consistent A2AR activation efficacy.

•        Concentration variants: Korean manufacturers produce PDRN products in a range of concentrations (mg/ml), allowing practitioners to select the appropriate concentration for their clinical application — lower concentrations for periorbital and sensitive zones, higher concentrations for scalp and large-area body treatments.

•        HA+PN hybrid products: Korean manufacturers have led the development of combined HA + PDRN single-formulation products — providing the hydration mechanism of HA alongside the regenerative mechanism of PDRN in a single injectable. These represent the most advanced current biorevitalisation formulation available.

PDRN vs European PN Products

Patient Selection: Who Benefits Most from PDRN

Combining PDRN with Other Treatments

PDRN is one of the most combinable injectables in aesthetic practice. For the full combination protocol guide, see our post on Combining Skin Boosters with Other Aesthetic Treatments. Key combination principles:

•        PDRN + HA skin booster: The most complementary of all injectable pairings. Combinable in the same session — no tissue conflict, completely different mechanisms. PN stimulates regeneration; HA provides hydration. The HA+PN hybrid products from Korean manufacturers combine both in one formulation.

•        PDRN + botulinum toxin: Same session acceptable. Toxin addresses movement; PDRN addresses skin quality. Botulax or Nabota (1:1 Botox-equivalent Korean toxins available through Celmade's botulinum toxin range) combine cleanly with PDRN in the same appointment.

•        PDRN + HA filler: Separate sessions preferred — 2-week minimum. PDRN at same session as filler is technically possible but separate sessions allow cleaner outcome attribution.

•        PDRN + microneedling: Separate sessions required — minimum 2 weeks after microneedling. Or PDRN applied topically via microneedling channels immediately post-procedure (topical application, not injectable).

•        PDRN + laser/energy devices: Separate sessions — minimum 4–6 weeks post-ablative, 2 weeks post non-ablative. Excellent evidence for PDRN as a post-laser recovery treatment.

Key Takeaways

•        PDRN works through a fundamentally different mechanism from HA skin boosters — A2AR-mediated fibroblast proliferation, VEGF upregulation, and salvage pathway nucleotide supply. Not hydration — regeneration.

•        The dual mechanism (trigger + supply) distinguishes PDRN from most other regenerative injectables — it both stimulates the regenerative process and provides the nucleotide raw materials that regenerating cells need.

•        PDRN has no hydrophilicity — making it the safest injectable for the periorbital zone and for any patient where post-treatment swelling is a concern.

•        The clinical evidence base is strong for wound healing and growing for aesthetic applications — with 15+ years of Korean real-world clinical data underpinning the global PDRN product category.

•        Korean PDRN products are the global clinical standard — CE marked, MFDS approved, produced under pharmaceutical GMP at significantly accessible pricing versus European alternatives.

•        PDRN and HA skin boosters are the most naturally combinable of all injectable pairings — complementary mechanisms, no tissue conflict, combinable in the same session.

•        Celmade's PDRN and PN range includes CE-marked Korean PDRN products across concentrations and formulations — including HA+PN hybrid products for the most advanced biorevitalisation protocols: browse the PDRN and PN collection.

For related cluster posts, see: PDRN for Under-Eye Rejuvenation, PDRN for Hair Rejuvenation, Complete Skin Boosters Guide, and Best Skin Boosters for Under-Eye Rejuvenation.

Frequently Asked Questions

What is the difference between PDRN and polynucleotides?

PDRN (polydeoxyribonucleotide) is the specific term for the DNA-based polynucleotide fraction used in aesthetic injectables. Polynucleotide (PN) is a broader term that includes both DNA-based and RNA-based nucleotide polymers. In practice, most aesthetic injectable products marketed as 'PN' or 'polynucleotides' contain PDRN — but it is worth confirming the specific composition with your supplier. The clinical evidence base reviewed in this guide is for PDRN-type (DNA-based) products.

Is PDRN safe for patients with fish allergies?

PDRN is derived from salmon or trout sperm DNA — it is processed nucleic acid, not fish protein. Most fish allergy reactions are to fish proteins (primarily parvalbumin), not to DNA. However, severe fish allergy warrants caution and a discussion with the patient about the source material. Review the specific product documentation from your supplier for allergy-related precautions. For patients with documented severe fish allergy, an allergy assessment before treatment is advisable.

How long does PDRN take to show results?

Results develop more slowly than HA skin boosters because the mechanism is regenerative rather than directly hydrating. Most patients begin to notice improvement in skin quality at 2–4 weeks after the first session. Meaningful improvement is typically visible at the 4-week review after session 2, and the full induction result is most apparent 4–6 weeks after the completion of session 3. Setting this timeline clearly at consultation prevents patients from assessing the treatment as ineffective after a single session.

Can PDRN be combined with HA skin boosters in the same session?

Yes — this is one of the most clinically sound and commonly performed combination approaches in advanced aesthetic practice. PDRN and HA skin boosters operate through completely different receptor pathways (A2AR for PDRN; water binding and RHAMM/CD44 for HA) with no tissue conflict and complementary effects. Many Korean manufacturers have responded to this clinical logic by producing HA+PN hybrid products that deliver both mechanisms from a single injection product.

How do Korean PDRN products compare to European alternatives like Nucleofill or Plinest?

Korean PDRN products are comparable in clinical efficacy to leading European products — the active ingredient (PDRN at a defined molecular weight range) and the mechanism (A2AR activation) are the same. The primary differences are in price point (Korean products are significantly more accessible — typically 40–70% lower wholesale cost at equivalent clinical quality), product range breadth (Korean manufacturers offer more concentration variants and combination products), and the depth of real-world clinical experience (15+ years of Korean domestic use provides an evidence base that no European product has accumulated). CE marking confirms that both meet the same European regulatory standard. For a full product range overview, see Celmade's PDRN and PN collection.